Adoptive T-cell therapy for Hodgkin lymphoma

CRISPR-engineered T cells in patients with refractory cancer

(2020) Edward A. Stadtmauer et al.   SCIENCE

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma

(2020) Carlos A. Ramos et al.   JOURNAL OF CLINICAL ONCOLOGY

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

(2019) Sarwish Rafiq et al.   Nature Reviews Clinical Oncology

Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma

(2019) Tomohiro Aoki et al.   Cancer Discovery

Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma

(2018) Jakub Svoboda et al.   BLOOD

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma

(2018) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication

(2018) Christopher C. Kloss et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor Therapy

(2018) Carl H. June et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

(2018) Joseph M. Connors et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

TGF-β in T Cell Biology: Implications for Cancer Immunotherapy

(2018) Amina Dahmani et al.   Cancers

EBV/LMP-specific T cells maintain remissions of T and B cell EBV lymphomas after allogeneic bone marrow transplantation

(2018) Lauren P. McLaughlin et al.   BLOOD

Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy

(2018) MAMTA KALRA et al.   CYTOTHERAPY

Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma

(2018) Xingliang Guo et al.   Frontiers in Pharmacology

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

(2017) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions

(2017) C A van der Weyden et al.   Blood Cancer Journal

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

(2017) Marco Ruella et al.   Cancer Discovery

HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?

(2017) Marcel Nijland et al.   OncoImmunology

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

(2016) R. Chen et al.   BLOOD

Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma

(2016) Baoping Guo et al.   BMC Medicine

Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial

(2016) Chun-Meng Wang et al.   CLINICAL CANCER RESEARCH

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Craig H Moskowitz et al.   LANCET

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophages and Dendritic Cells as Actors in the Immune Reaction of Classical Hodgkin Lymphoma

(2014) Christiane Silke Tudor et al.   PLoS One

Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

(2013) Catherine M. Bollard et al.   JOURNAL OF CLINICAL ONCOLOGY

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy

(2013) Liza B John et al.   OncoImmunology

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

Hodgkin lymphoma

(2012) Ralf Küppers et al.   JOURNAL OF CLINICAL INVESTIGATION

Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

(2012) Leo I. Gordon et al.   JOURNAL OF CLINICAL ONCOLOGY

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

(2011) E. Doubrovina et al.   BLOOD

Molecular Pathogenesis of Hodgkin's Lymphoma: Increasing Evidence of the Importance of the Microenvironment

(2011) Christian Steidl et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma

(2010) Jonathan R. Fromm   CYTOMETRY PART B-CLINICAL CYTOMETRY

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

(2010) Andreas Engert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating clonotypic B cells in classic Hodgkin lymphoma

(2009) R. J. Jones et al.   BLOOD

T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model

(2009) A. Di Stasi et al.   BLOOD

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

(2009) H. E. Heslop et al.   BLOOD

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

(2008) A. Bashey et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-?? Receptor

(2008) Aaron E. Foster et al.   JOURNAL OF IMMUNOTHERAPY